Arsanis Inc (ASNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Arsanis Inc (ASNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH306646D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Arsanis Inc (Arsanis) is a clinical-stage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company's pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets respiratory syncytial virus (RSV); ASN300, for klebsiella pneumonia; and ASN200, for escherichia coli. Arsanis works in collaboration with industry, academic and clinical research groups for antibody discovery and development. The company is funded by SV Life Sciences, OrbiMed, NeoMed, Polaris Ventures, and EMBL Ventures among others. It has operational presence in the US and Austria. Arsanis is headquartered in Waltham, Massachusetts, the US.

Arsanis Inc (ASNS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arsanis Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Arsanis Raises USD45.5 Million in Series D Financing 11

Arsanis Raises USD15 million in Venture Financing 13

Arsanis Raises USD4 Million Financing 14

Arsanis Raises USD 20 Million In Series B Financing 15

Licensing Agreements 17

BB200 Enters into Licensing Agreement with Arsanis 17

BB100 Enters into Licensing Agreement with Arsanis 18

Arsanis Enters into Licensing Agreement with Adimab 19

Equity Offering 20

Arsanis Raises USD46 Million in IPO of Shares 20

Arsanis Raises USD20 Million in Private Placement of Shares 22

Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23

Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24

Debt Offering 25

Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25

Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26

Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27

Arsanis Inc-Key Competitors 28

Arsanis Inc-Key Employees 29

Arsanis Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 13, 2018: Arsanis Reports Financial Results for Second Quarter 2018 31

May 10, 2018: Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 33

Mar 09, 2018: Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 35

Corporate Communications 37

Oct 04, 2017: Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer 37

Product News 38

04/17/2018: Arsanis to Present Abstract On ASN500 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 38

04/17/2018: Arsanis to Present Poster On ASN100 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 39

Clinical Trials 40

Oct 09, 2017: Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017 40

Sep 08, 2017: Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 41

Apr 20, 2017: Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Disease 42

Jan 24, 2017: Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Arsanis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arsanis Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arsanis Raises USD45.5 Million in Series D Financing 11

Arsanis Raises USD15 million in Venture Financing 13

Arsanis Raises USD4 Million Financing 14

Arsanis Raises USD 20 Million In Series B Financing 15

BB200 Enters into Licensing Agreement with Arsanis 17

BB100 Enters into Licensing Agreement with Arsanis 18

Arsanis Enters into Licensing Agreement with Adimab 19

Arsanis Raises USD46 Million in IPO of Shares 20

Arsanis Raises USD20 Million in Private Placement of Shares 22

Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23

Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24

Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25

Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26

Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27

Arsanis Inc, Key Competitors 28

Arsanis Inc, Key Employees 29

Arsanis Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Arsanis Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17833
Site License
USD 500 INR 35665
Corporate User License
USD 750 INR 53498

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com